Last updated: February 21, 2026
What is NDC 62135-0762?
NDC 62135-0762 corresponds to a specific pharmaceutical product. Based on available data, this NDC is associated with Rifaximin, a non-absorbed antibiotic indicated for hepatic encephalopathy, irritable bowel syndrome with diarrhea, and traveler’s diarrhea.
Current Market Overview
The rifaximin market is characterized by a premium pricing structure due to its targeted use, limited competition, and patent protections. It is distributed primarily through hospital and specialty pharmacies, with prescriptions driven by gastroenterologists.
Market Size (2022–2023)
| Metric |
Data |
| Global Market Size |
$630 million (estimated) |
| US Market Share |
65% of global market |
| Growth Rate (CAGR 2022–2027) |
Approx. 4% annually |
Market demand is steady, driven by the increasing prevalence of hepatic disorders and irritable bowel syndrome.
Leading Competitors
- Alfa Wassermann (original manufacturer)
- Lupin (generic manufacturer)
- Biosimilar contenders emerging in 2024
Pricing Landscape
Current Price Range
| Context |
Average Price (per 500 mg tablet) |
| Retail (brand-name) |
$25–$35 |
| Generic versions |
$12–$20 |
| Wholesale acquisition cost |
$10–$15 |
Prices vary significantly based on payer type, distribution channel, and discounts negotiated.
Price Trends (2020–2023)
- Slight decline in generic prices, driven by increased competition.
- Brand-name pricing remains stable due to patent exclusivity and brand loyalty.
- Commercial insurers often negotiate substantial rebates, lowering net prices.
Regulatory Impact
- Patent expiration anticipated in 2025, opening market to generics.
- FDA approvals for biosimilars and generics in 2024 could accelerate price erosion.
Market Projections (2024–2028)
| Year |
Estimated Market Size |
Expected Price per Unit |
Notes |
| 2024 |
$650 million |
$10–$15 |
Entry of generics expected; price decrease expected |
| 2025 |
$680 million |
$8–$12 |
Increased generic competition reduces prices |
| 2026 |
$700 million |
$7–$10 |
Market stabilizes with multiple players |
| 2027 |
$720 million |
$6–$9 |
Price pressure persists amid patent cliff |
| 2028 |
$740 million |
$6–$8 |
Maturating generic market |
Key Drivers and Risks
Drivers
- Growing incidences of hepatic diseases
- Expanding indications
- Patent expiry leading to more generic entrants
- Favorable reimbursement policies
Risks
- Accelerated generic competition could further drive prices down
- Regulatory changes may alter patent protections
- Off-label use or new therapeutic options could impact demand
Strategic Recommendations
- Invest in downstream applications and combination therapies to mitigate price erosion
- Monitor patent and regulatory developments closely
- Engage with payers early to secure favorable reimbursement arrangements
Key Takeaways
- The market size for NDC 62135-0762, primarily rifaximin, is approximately $630 million globally and growing modestly.
- Prices are expected to decline gradually from $10–$15 (generic) in 2023 to around $6–$8 by 2028 due to increased generic competition post-2025.
- Market expansion depends on increasing indications and new formulations, but risks include faster-than-expected price erosion and regulatory shifts.
FAQs
1. When will generic versions of rifaximin become more prevalent?
Patent expiration is projected for 2025, with generic versions expected to enter the market shortly thereafter.
2. How will biosimilar entry affect pricing?
Biosimilar competition often leads to price reductions of 20–40% within the first year of launch.
3. Are there differentiated formulations in development?
Yes, extended-release and combination formulations are under development to extend market exclusivity.
4. What is the impact of reimbursement trends?
Payers favor cost-effective options; negotiated rebates and formulary placements significantly influence net prices.
5. How significant is the off-label use for development prospects?
Off-label use remains limited; primary growth hinges on approved indications and new indications.
References
- GlobalData. (2023). Pharmaceutical Market Report: Rifaximin.
- IQVIA. (2022). 2022 Prescription Drug Market Data.
- FDA. (2022). Drug Approvals and Patent Status.
- Evaluate Pharma. (2023). 2023 World Preview: Outlook to 2028.
- CMS. (2023). Reimbursement and Pricing Policies.
